Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
NCT05448885
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
Tislelizumab
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences